



Flexion Therapeutics, Inc.
Investor Relations Department
10 Mall Road
Suite 301
Burlington, MA 01803
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

Last Trade:	25.03
Trade Time:	4:00 PM ET Jan 16, 2018
Change:	-1.42 ▼ (-5.369%)
Day Range	25.01 - 26.90
52-Week Range	16.51 - 32.25
Volume	813,444

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 8, 2018

[Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\)](#)

Dec 18, 2017

[Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Osteoarthritis of the Shoulder and Hip](#)

Dec 13, 2017

[Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee](#)

Dec 11, 2017

[Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer](#)

Dec 7, 2017

[Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Bilateral Osteoarthritis of the Knee](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 10, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

